SCHEMBL6324871

SCHEMBL6324871

CC1(C)Cc2cccc3c(C4=C(c5c[nH]c6ccccc56)C(=O)NC4=O)cn(c23)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 9/20 0.62
CCND1 P24385 9/20 0.62
PRKACA P17612 10/20 0.54
PRKACG P22612 10/20 0.54
PRKACB P22694 10/20 0.54
PRKCB P05771 8/20 0.54
PRKCA P17252 8/20 0.54
PRKCH P24723 8/20 0.54
PRKCE Q02156 8/20 0.54
PRKCD Q05655 8/20 0.54
PRKCQ Q04759 7/20 0.54
CDK2 P24941 5/20 0.54
CAMK2D Q13557 5/20 0.54
CCNE2 O96020 4/20 0.54
CCNE1 P24864 4/20 0.54
PRKCG P05129 4/20 0.54
PRKCZ Q05513 4/20 0.54
PRKD3 O94806 3/20 0.54
CDK1 P06493 3/20 0.54
PIM1 P11309 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330097 0.89 CDK4 (0.67) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL2343710 0.83 CDK4 (0.63) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL6334270 0.82 CDK4 (0.74) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL224940 0.81 CDK4 (0.61) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL13056770 0.80 CDK4 (0.61) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL6329959 0.80 CDK4 (0.60) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL6802730 0.79 GSK3A (0.65) GSK3BGSK3A
SCHEMBL6332977 0.77 CDK4 (0.55) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL6327991 0.77 CDK4 (0.55) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL6327845 0.77 CDK4 (0.78) CDK4CCND1PRKACAPRKACGPRKACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867198-B2 Agents and methods for the treatment of proliferative diseases ELI LILLY AND COMPANY (US) 2005-03-15 US disclosed
US-20030229026-A1 Agents and methods for the treatment of proliferative diseases ELI LILLY AND COMPANY 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229026-A1 Agents and methods for the treatment of proliferative diseases MKI67, CDKN1A, CDK1 CDK4 5/4885CCND1 70/4885PRKACA 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.